LEKTI Antibody (F-2): sc-166604

LEKTI Antibody (F-2) is a mouse monoclonal IgG1 antibody that detects Lympho-epithelial Kazal-type inhibitor (LEKTI) in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). LEKTI is a crucial serine protease inhibitor that plays a significant role in protecting mucous epithelia from microbial invasion and inflammation, thereby maintaining the integrity of epithelial barriers. LEKTI (F-2) antibody detects LEKTI predominantly in the granular and uppermost spinous layers of the epidermis, as well as in the differentiated layers of stratified epithelia, which is vital for its function in epithelial differentiation and defense mechanisms. Notably, mutations in the SPINK5 gene, which encodes LEKTI, are linked to Netherton syndrome, a severe autosomal recessive disorder characterized by atopic dermatitis, hay fever, and other related conditions. LEKTI (F-2) monoclonal antibody serves as an essential tool for researchers studying epithelial biology and related pathologies, providing insights into the mechanisms of skin barrier function and the implications of LEKTI deficiency in various diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

LEKTI Antibody (F-2) References:

1. LEKTI, a novel 15-domain type of human serine proteinase inhibitor.  |  Mägert, HJ., et al. 1999. J Biol Chem. 274: 21499-502. PMID: 10419450
2. LEKTI: a multidomain serine proteinase inhibitor with pathophysiological relevance.  |  Mägert, HJ., et al. 2002. Int J Biochem Cell Biol. 34: 573-6. PMID: 11943586
3. LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome.  |  Bitoun, E., et al. 2003. Hum Mol Genet. 12: 2417-30. PMID: 12915442
4. LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum.  |  Ishida-Yamamoto, A., et al. 2005. J Invest Dermatol. 124: 360-6. PMID: 15675955
5. Netherton syndrome in two Japanese siblings with a novel mutation in the SPINK5 gene: immunohistochemical studies of LEKTI and other epidermal molecules.  |  Shimomura, Y., et al. 2005. Br J Dermatol. 153: 1026-30. PMID: 16225619
6. Crystal structure of human epidermal kallikrein 7 (hK7) synthesized directly in its native state in E. coli: insights into the atomic basis of its inhibition by LEKTI domain 6 (LD6).  |  Fernández, IS., et al. 2008. J Mol Biol. 377: 1488-97. PMID: 18329042
7. LEKTI-1 in sickness and in health.  |  Roelandt, T., et al. 2009. Int J Cosmet Sci. 31: 247-54. PMID: 19467033
8. Human involucrin promoter mediates repression-resistant and compartment-specific LEKTI expression.  |  Di, WL., et al. 2012. Hum Gene Ther. 23: 83-90. PMID: 21895535
9. Netherton syndrome and its multifaceted defective protein LEKTI.  |  D'Alessio, M., et al. 2013. G Ital Dermatol Venereol. 148: 37-51. PMID: 23407075
10. LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: implications for targeted therapy of Netherton syndrome.  |  Wiegmann, H., et al. 2019. Br J Dermatol. 181: 999-1008. PMID: 30801672

The preferred LEKTI antibody is LEKTI Antibody (E-9): sc-137109.